BeOne Medicines Reports Q3 2026 Financial Results and Raises Full-Year Guidance

Executive Summary

On November 5, 2026, BeOne Medicines Ltd. filed a Current Report on Form 8-K furnishing its financial results for the third quarter ended September 30, 2026 (Item 2.02). The company reported strong operational momentum led by its flagship BTK inhibitor BRUKINSA and raised its full-year 2026 financial guidance.

Third Quarter 2026 Financial Highlights

• Total Revenue: Reached $1.89 billion for Q3 2026, representing a 34% increase compared to $1.41 billion in Q3 2025.
  • Net Product Revenue: $1.86 billion, up 33% year-over-year.
  • Other Revenue: $34.8 million, up 101% year-over-year.
• Product Performance:
  • BRUKINSA (zanubrutinib): Global revenue totaled $1.4 billion (+34% YoY), with U.S. sales contributing $1.0 billion (+36% YoY).
  • TEVIMBRA (tislelizumab): Global revenue was $243 million (+28% YoY).
  • Amgen In-Licensed Products: Generated $167 million (+26% YoY).
• Profitability Metrics:
  • GAAP Operating Income: $418.7 million, up 157% from $163.1 million in Q3 2025.
  • Adjusted Operating Income: $612.2 million, up 79% from $341.2 million in Q3 2025.
  • GAAP Net Income: $384.7 million ($3.28 per diluted ADS), compared to $124.8 million ($1.09 per diluted ADS) in the prior-year period.
  • Adjusted Net Income: $538.7 million ($4.59 per diluted ADS), up 77% YoY.
• Free Cash Flow: $473.5 million for the quarter, an increase of 34% from $354.5 million in Q3 2025.

Updated Full-Year 2026 Guidance

BeOne Medicines raised its full-year 2026 financial outlook:

• Total Revenue: $6.9 billion to $7.0 billion
• GAAP Operating Income: $1.2 billion to $1.3 billion
• Non-GAAP Operating Income: $1.9 billion to $2.0 billion